Nilotinib Eg (Nilotinib)

Nilotinib binds selectively to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, blocking its enzymatic activity. This interruption halts downstream signaling pathways that promote uncontrolled cell growth, leading to reduced proliferation of leukemic cells and induction of apoptosis.

The specific dose of Nilotinib Eg is determined by the prescribing clinician based on the patient’s disease status, prior therapies, and individual health factors. Dosing regimens are individualized and should follow the prescriber’s written instructions.

Nilotinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended while on nilotinib because the drug may be excreted in milk.

To request Nilotinib Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity compared with first‑generation agents like imatinib. Clinical data suggest faster and deeper molecular responses, though safety profiles differ, requiring attention to cardiac and metabolic adverse effects.

Store Nilotinib Eg tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and avoid storing in areas with high humidity or temperature fluctuations.

Nilotinib Eg is taken orally as a tablet, usually with a low‑fat meal to improve absorption. The tablet should be swallowed whole with water and not crushed or chewed. Patients should follow the prescriber’s dosing schedule and timing instructions.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe hepatic toxicity, and pancreatitis. Regular cardiac monitoring, liver function tests, and prompt reporting of symptoms such as palpitations or abdominal pain are essential.

Nilotinib Eg should be avoided in patients with a known hypersensitivity to nilotinib or any tablet excipients, in those with a history of significant QT prolongation, uncontrolled electrolyte disturbances, or severe hepatic impairment. It is also contraindicated during pregnancy unless absolutely necessary.